PRESS RELEASE published on 01/24/2024 at 20:00, 1 year 10 months ago TransAstra Awarded First Defense Department Contract for FlyTrap, Following Success With NASA TransAstra, innovators in space logistics and orbital debris management, secures a research and development contract for its FlyTrap technology from the United States Department of Defense. The FlyTrap technology, which has already received NASA contracts, is designed to safely capture and secure uncooperative space objects, offering a value-enhancing end-of-life mission solution for revenue-generating satellites. The collaboration with the University of Michigan and AFWERX highlights the industry recognition of FlyTrap's capabilities. TransAstra aims to revolutionize space safety and sustainability with its groundbreaking technology. Department Of Defense TransAstra FlyTrap Technology Orbital Debris Management Space Logistics
PRESS RELEASE published on 10/24/2023 at 18:00, 2 years 1 month ago TransAstra's FlyTrap Honored by TIME as a Special Mention in the Best Inventions of 2023
Published on 12/05/2025 at 02:35, 4 hours 5 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 40 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 35 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 40 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 3 hours 10 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 49 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 15 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 25 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 29 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:14, 12 hours 25 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 12 hours 40 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 12 hours 40 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 55 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 12 hours 55 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
